Reduced Expression of Galectin-8 May Contribute in Carcinogenic Pathway of Head and Neck Squamous Cell Carcinoma.
Galectin-8 Head and Neck Squamous Cell Carcinoma Immunohistochemistry
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
02
2020
accepted:
12
11
2020
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
ppublish
Résumé
Galectin-8 has relationships with cell growth and metastasis of some cancers. Due to controversy in the clinical significance of this protein in the cancer process, we investigated its roles in the development of head and neck squamous cell carcinoma. This study was performed on 93 samples of patients with Squamous Cell Carcinoma or dysplasia of the head and neck, who underwent biopsy or surgery from 2015 till 2017 in Boo-Ali SINA hospital of Sari, Iran. The relevant paraffin embedded tissue blocks were obtained from archive of pathology and evaluated for galectin-8 by immunohistochemistry. The association between expression of galactin-8 and age, sex, location and stage of disease were assessed. To compare expression rate between the groups, Mc-Nemar, Chi-square and Fisher's exact tests were used. The P-value<0.05 was considered significant. Strong cytoplasmic and nuclear galactin-8 staining was observed in 97.6% cases of normal tissues while 77% of dysplastic lesions and 69% of the cancers revealed negative immunoreactivity. The intensity of expression in dysplastic and malignant tissues was significantly reduced compared with normal tissues ( We observed that the expression of galectin-8 in dysplastic and malignant squamous epithelium significantly reduced compared with the normal counterpart of them in the head and neck. It may contribute to malignant transformation of head and neck squamous cells.
Sections du résumé
BACKGROUND & OBJECTIVE
OBJECTIVE
Galectin-8 has relationships with cell growth and metastasis of some cancers. Due to controversy in the clinical significance of this protein in the cancer process, we investigated its roles in the development of head and neck squamous cell carcinoma.
METHODS
METHODS
This study was performed on 93 samples of patients with Squamous Cell Carcinoma or dysplasia of the head and neck, who underwent biopsy or surgery from 2015 till 2017 in Boo-Ali SINA hospital of Sari, Iran. The relevant paraffin embedded tissue blocks were obtained from archive of pathology and evaluated for galectin-8 by immunohistochemistry. The association between expression of galactin-8 and age, sex, location and stage of disease were assessed. To compare expression rate between the groups, Mc-Nemar, Chi-square and Fisher's exact tests were used. The P-value<0.05 was considered significant.
RESULTS
RESULTS
Strong cytoplasmic and nuclear galactin-8 staining was observed in 97.6% cases of normal tissues while 77% of dysplastic lesions and 69% of the cancers revealed negative immunoreactivity. The intensity of expression in dysplastic and malignant tissues was significantly reduced compared with normal tissues (
CONCLUSION
CONCLUSIONS
We observed that the expression of galectin-8 in dysplastic and malignant squamous epithelium significantly reduced compared with the normal counterpart of them in the head and neck. It may contribute to malignant transformation of head and neck squamous cells.
Identifiants
pubmed: 33936231
doi: 10.30699/IJP.2021.121140.2318
pmc: PMC8085289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
195-204Références
Clin Exp Otorhinolaryngol. 2009 Mar;2(1):13-9
pubmed: 19434286
Oncol Rep. 2002 Jan-Feb;9(1):177-80
pubmed: 11748478
Glycoconj J. 2004;19(7-9):433-40
pubmed: 14758066
J Leukoc Biol. 2009 Aug;86(2):371-80
pubmed: 19401394
Cancers (Basel). 2019 Dec 20;12(1):
pubmed: 31861875
Urol Int. 2011;87(2):143-50
pubmed: 21757871
Glycobiology. 2014 Oct;24(10):907-14
pubmed: 24939370
Cancers (Basel). 2010 Apr 20;2(2):592-610
pubmed: 23658855
Curr Opin Immunol. 2017 Apr;45:8-15
pubmed: 28088061
Sci Rep. 2017 Oct 16;7(1):13244
pubmed: 29038585
Anticancer Res. 2009 Dec;29(12):4933-40
pubmed: 20044599
Cell Mol Life Sci. 2007 Jul;64(13):1679-700
pubmed: 17497244
Clin Cancer Res. 2011 Nov 15;17(22):7035-46
pubmed: 21933892
Oncotarget. 2017 Jul 4;8(27):44654-44668
pubmed: 28591719
Mol Neurobiol. 2019 Nov;56(11):7774-7788
pubmed: 31119556
Oncol Rep. 2008 Mar;19(3):587-94
pubmed: 18288388
Glycoconj J. 2004;19(7-9):557-63
pubmed: 14758080
Front Chem. 2020 Aug 07;8:593
pubmed: 32850631
Mediators Inflamm. 2018 May 21;2018:9186940
pubmed: 29950926
Glycoconj J. 2004;19(7-9):517-26
pubmed: 14758075
Histopathology. 2011 Mar;58(4):543-56
pubmed: 21410745
Int J Mol Sci. 2017 Dec 18;18(12):
pubmed: 29258258
Histol Histopathol. 2001 Jul;16(3):861-8
pubmed: 11510978
J Leukoc Biol. 2017 Nov;102(5):1237-1247
pubmed: 28811319
Front Cell Infect Microbiol. 2020 Jul 02;10:285
pubmed: 32714876
Expert Rev Mol Med. 2008 Jun 13;10:e17
pubmed: 18549522
Int J Cancer. 2011 Jul 1;129(1):1-8
pubmed: 21520033
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389859
Oncol Rep. 2009 Apr;21(4):983-7
pubmed: 19287997
Oncol Rep. 2014 Jul;32(1):23-32
pubmed: 24859692
Dent Res J (Isfahan). 2013 Jul;10(4):428-33
pubmed: 24130575